Imagion Biosystems Ltd. · ASX:IBX
Imagion Biosystems — Investor Presentation (September 2019)
17 slides from Imagion Biosystems's investor presentation, Sep 9, 2019
Slide 1: Imagion commences Non Deal Roadshow in Australia
® B I O S Y S T E M S ® IMAGION BIOSYSTEMS LIMITED (ASX: IBX) 9 September 2019 Imagion commences Non Deal Roadshow in Australia MELBOURNE — Imagion Biosystems Limited (ASX: IBX) (the Company), a company dedicated to improving healthcare through the earlier detection of cancer is pleased to share the
Slide 2: MagSense Technology: Early Detection of Cancer Through Targeted Imaging
® B I O S Y S T E M S MagSense™ Technology Early Detection of Cancer Through Targeted Imaging ASX:IBX www.imagionbiosystems.com
Slide 3: Disclaimer
DISCLAIMER This investor presentation (Presentation) has been prepared by Imagion Biosystems Limited (Imagion or the Company). This presentation does not constitute or form part of, and should not be construed as, an offer, solicitation or invitation to subscribe for, underwrite or otherwise acquire
Slide 4: People are affected by Cancer
1 in 3 People are affected by Cancer “Early detection of many diseases, particularly cancers, is key to successful treatment.” “Despite technical advances in many areas of diagnostic radiology, the detection and imaging of human cancer remains poor. “ Chemical Reviews 2015 Nanoparticles in Medicine
Slide 5: Medical Imaging Breakthrough
MEDICAL IMAGING BREAKTHROUGH MagSense™ Technology will transform cancer diagnosis • Non-invasive, non-radioactive – a safe and non-surgical solution to detect cancer • Uses bio-safe tiny nanoparticles to “tag” cancer cells • FDA Breakthrough Designation supports transformative status • First indicat
Slide 6: Experienced Team
EXPERIENCED TEAM Commercially focused team with deep industry & clinical experience World class scientific collaborations & partnerships: ROBERT PROULX MICHAEL HARSH DAVID LUDVIGSON BRONWYN LE GRICE CHAIRMAN & CEO NON EXEC DIRECTOR NON EXEC DIRECTOR NON EXEC DIRECTOR • Operationally oriented • Forme
Slide 7: Capital Structure
C A P I TA L S T R U C T U R E Ordinary shares on issue 323.71M Share price (5 Sept 2019) 0.041 Average daily volume 4.77M Price ( AUD) Market capitalization 12.62M $0.056 Net cash (30 June 2019) $1.1M $0.046 (+ further $2M via R&D tax credit in July) $0.036 Major Shareholders Manhattan Scientifics
Slide 8: Clear Unmet Medical Need
CLEAR UNMET MEDICAL NEED 50 years since last new imaging technology was introduced Current technologies: • Identify a “region of interest” • Expose patients to radiation • Require invasive biopsies to confirm • Result in unnecessary biopsies IMAGIONBIOSYSTEMS.COM | 7
Slide 9: How It Works
HOW IT WORKS Bio-safe magnetic nanoparticles are attracted to the tumor and detected • Nanoparticles, specific for the cancer, bind to tumor cells • Nanoparticles demagnetize or “relax” after exposure to a low magnetic field • Nanoparticles attached to cancer cells “relax” more slowly than particles
Slide 10: Strategic Plan
S T R AT E G I C P L A N Path to future products & value STAGING TUMOR MRI TREATMENT DOCTORS DETECTION & BREAST CANCER DETECTION CONTRAST MONITORING OFFICE THERAPY Reduce unnecessary Breast, prostate, lung Safer alternative to Monitor tumor size Hand-held MagSense Provide both surgery & ovarian curr
Slide 11: Designated Breakthrough Device
D E S I G N AT E D B R E A K T H R O U G H D E V I C E First indication – metastatic breast cancer – provides fastest path to commercialisation IMPROVES PATIENT OUTCOMES The MagSense™ system and test has • Staging of metastatic HER2+ breast cancer eliminates been designated FDA Breakthrough lymphade
Slide 12: Transformative, Not Disruptive
T R A N S F O R M AT I V E , N O T D I S R U P T I V E Improved outcomes, within existing clinical workflow MagSense replaces current non- functional imaging Eliminates unnecessary biopsies for negative patients In ~50% of cases lymph nodes are removed unnecessarily IMAGIONBIOSYSTEMS.COM | 11
Slide 13: Milestones and Valuation Drivers
M I L E S TO N E S A N D VA L U AT I O N D R I V E R S Indicative development timeline and key inflection points* • Toxicology study provided key safety data enabling path to human studies. Lead Formulation Identified • Manufacturing of material for use in human study in process. • Clearance by regu
Slide 14: Major Players Are Investing
M A J O R P L AY E R S A R E I N V E S T I N G Creating markets creates multi-billion dollar deals Deal Size US#370M Undisclosed US$85M US$716M US$1.7B Undisclosed Year 2019 2019 2019 2017 2017 2017 Acquirer Target Technology Mobile CT Cloud- Medical Flouresence Medical Image scanner and enabled ima
Slide 15: Strong R&D Pipeline
STRONG R&D PIPELINE Product Applications Under Development Research Pre-Clinical Clinical Design In Vitro Animal Models Tox/Safety Early Feasibility Pivotal Metastatic HER2 Breast Cancer MagSense Invasive Breast Pipeline Cancer • The basic nanoparticle formulation is consistent across different canc
Slide 16: Investment Highlights
INVESTMENT HIGHLIGHTS LARGE OPPORTUNITY UNIQUE TECHNOLOGY $100B cancer diagnostic market New form of medical imaging Growing 7% annually Molecularly specific & non-invasive Medical imaging commands largest share More sensitive than current methods Under-addressed need for early diagnosis Protected b
Slide 17: Imagion Biosystems
® B I O S Y S T E M S IMAGION BIOSYSTEMS www.imagionbiosystems.com
Imagion Biosystems — Investor Presentation (September 2019) on 6ix